Bismuth subsalicylate in the treatment of acute diarrhea in children

A clinical study

H. Soriano-Brucher, P. Avendano, M. O'Ryan, S. D. Braun, M. D. Manhart, T. K. Balm, H. A. Soriano

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Bismuth subsalicylate (BSS) and placebo were evaluated in a double-blind, placebo-controlled study as adjunct to rehydration therapy in 123 children, aged 4 to 28 months, hospitalized with acute diarrhea. The dosing regimen was 20 mg/kg five times daily for 5 days. Significant benefits were noted in the BSS group compared with placebo as manifested by decreases in stool frequency and stool weights and an improvement in stool consistency, significant improvement in clinical well-being, and shortening of the disease duration. Patients treated with BSS had a significant reduction in duration of hospital stay (6.9 days) compared with placebo-treated patients (8.5 days). Also, intravenous fluid requirements decreased significantly more rapidly and to a greater degree in the BSS-treated group. Bismuth subsalicylate was associated with clearance of pathogenic Escherichia coli from the stools in 100% of cases but was not different from placebo in rotavirus elimination. Bismuth subsalicylate was well tolerated with no reported adverse effects. Blood bismuth and serum salicylate levels were well below levels considered toxic. In this study, BSS provided effective adjunctive therapy for acute diarrhea, allowing children to get well sooner with less demand on the nursing and hospital staff.

Original languageEnglish (US)
Pages (from-to)18-27
Number of pages10
JournalPediatrics
Volume87
Issue number1
StatePublished - Jan 1 1991

Fingerprint

Diarrhea
Placebos
Therapeutics
Hospital Nursing Staffs
Rotavirus
Fluid Therapy
Poisons
bismuth subsalicylate
Clinical Studies
Length of Stay
Escherichia coli
Weights and Measures
Serum

Keywords

  • antidiarrheals
  • bismuth subsalicylate
  • diarrhea
  • gastroenteritis

Cite this

Soriano-Brucher, H., Avendano, P., O'Ryan, M., Braun, S. D., Manhart, M. D., Balm, T. K., & Soriano, H. A. (1991). Bismuth subsalicylate in the treatment of acute diarrhea in children: A clinical study. Pediatrics, 87(1), 18-27.

Bismuth subsalicylate in the treatment of acute diarrhea in children : A clinical study. / Soriano-Brucher, H.; Avendano, P.; O'Ryan, M.; Braun, S. D.; Manhart, M. D.; Balm, T. K.; Soriano, H. A.

In: Pediatrics, Vol. 87, No. 1, 01.01.1991, p. 18-27.

Research output: Contribution to journalArticle

Soriano-Brucher, H, Avendano, P, O'Ryan, M, Braun, SD, Manhart, MD, Balm, TK & Soriano, HA 1991, 'Bismuth subsalicylate in the treatment of acute diarrhea in children: A clinical study', Pediatrics, vol. 87, no. 1, pp. 18-27.
Soriano-Brucher H, Avendano P, O'Ryan M, Braun SD, Manhart MD, Balm TK et al. Bismuth subsalicylate in the treatment of acute diarrhea in children: A clinical study. Pediatrics. 1991 Jan 1;87(1):18-27.
Soriano-Brucher, H. ; Avendano, P. ; O'Ryan, M. ; Braun, S. D. ; Manhart, M. D. ; Balm, T. K. ; Soriano, H. A. / Bismuth subsalicylate in the treatment of acute diarrhea in children : A clinical study. In: Pediatrics. 1991 ; Vol. 87, No. 1. pp. 18-27.
@article{c1be4bf7d72a45ab9343207beb8ef782,
title = "Bismuth subsalicylate in the treatment of acute diarrhea in children: A clinical study",
abstract = "Bismuth subsalicylate (BSS) and placebo were evaluated in a double-blind, placebo-controlled study as adjunct to rehydration therapy in 123 children, aged 4 to 28 months, hospitalized with acute diarrhea. The dosing regimen was 20 mg/kg five times daily for 5 days. Significant benefits were noted in the BSS group compared with placebo as manifested by decreases in stool frequency and stool weights and an improvement in stool consistency, significant improvement in clinical well-being, and shortening of the disease duration. Patients treated with BSS had a significant reduction in duration of hospital stay (6.9 days) compared with placebo-treated patients (8.5 days). Also, intravenous fluid requirements decreased significantly more rapidly and to a greater degree in the BSS-treated group. Bismuth subsalicylate was associated with clearance of pathogenic Escherichia coli from the stools in 100{\%} of cases but was not different from placebo in rotavirus elimination. Bismuth subsalicylate was well tolerated with no reported adverse effects. Blood bismuth and serum salicylate levels were well below levels considered toxic. In this study, BSS provided effective adjunctive therapy for acute diarrhea, allowing children to get well sooner with less demand on the nursing and hospital staff.",
keywords = "antidiarrheals, bismuth subsalicylate, diarrhea, gastroenteritis",
author = "H. Soriano-Brucher and P. Avendano and M. O'Ryan and Braun, {S. D.} and Manhart, {M. D.} and Balm, {T. K.} and Soriano, {H. A.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "87",
pages = "18--27",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Bismuth subsalicylate in the treatment of acute diarrhea in children

T2 - A clinical study

AU - Soriano-Brucher, H.

AU - Avendano, P.

AU - O'Ryan, M.

AU - Braun, S. D.

AU - Manhart, M. D.

AU - Balm, T. K.

AU - Soriano, H. A.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Bismuth subsalicylate (BSS) and placebo were evaluated in a double-blind, placebo-controlled study as adjunct to rehydration therapy in 123 children, aged 4 to 28 months, hospitalized with acute diarrhea. The dosing regimen was 20 mg/kg five times daily for 5 days. Significant benefits were noted in the BSS group compared with placebo as manifested by decreases in stool frequency and stool weights and an improvement in stool consistency, significant improvement in clinical well-being, and shortening of the disease duration. Patients treated with BSS had a significant reduction in duration of hospital stay (6.9 days) compared with placebo-treated patients (8.5 days). Also, intravenous fluid requirements decreased significantly more rapidly and to a greater degree in the BSS-treated group. Bismuth subsalicylate was associated with clearance of pathogenic Escherichia coli from the stools in 100% of cases but was not different from placebo in rotavirus elimination. Bismuth subsalicylate was well tolerated with no reported adverse effects. Blood bismuth and serum salicylate levels were well below levels considered toxic. In this study, BSS provided effective adjunctive therapy for acute diarrhea, allowing children to get well sooner with less demand on the nursing and hospital staff.

AB - Bismuth subsalicylate (BSS) and placebo were evaluated in a double-blind, placebo-controlled study as adjunct to rehydration therapy in 123 children, aged 4 to 28 months, hospitalized with acute diarrhea. The dosing regimen was 20 mg/kg five times daily for 5 days. Significant benefits were noted in the BSS group compared with placebo as manifested by decreases in stool frequency and stool weights and an improvement in stool consistency, significant improvement in clinical well-being, and shortening of the disease duration. Patients treated with BSS had a significant reduction in duration of hospital stay (6.9 days) compared with placebo-treated patients (8.5 days). Also, intravenous fluid requirements decreased significantly more rapidly and to a greater degree in the BSS-treated group. Bismuth subsalicylate was associated with clearance of pathogenic Escherichia coli from the stools in 100% of cases but was not different from placebo in rotavirus elimination. Bismuth subsalicylate was well tolerated with no reported adverse effects. Blood bismuth and serum salicylate levels were well below levels considered toxic. In this study, BSS provided effective adjunctive therapy for acute diarrhea, allowing children to get well sooner with less demand on the nursing and hospital staff.

KW - antidiarrheals

KW - bismuth subsalicylate

KW - diarrhea

KW - gastroenteritis

UR - http://www.scopus.com/inward/record.url?scp=0026097998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026097998&partnerID=8YFLogxK

M3 - Article

VL - 87

SP - 18

EP - 27

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1

ER -